CDER and ORA Enter Facilities/Inspections CoOps

Article

FDA’S CDER and ORA have entered into a concept of operations agreement to integrate facility evaluations and inspections for human drugs.

FDA’s Center for Drug Evaluation and Research (CDER) and Office of Regulatory Affairs (ORA) have entered into a concept of operations (ConOps) agreement to integrate facility evaluations and inspections for human drugs. The agreement, Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations, outlines the responsibilities and workflow for pre-approval, post-approval, surveillance, and for-cause inspections at domestic and international facilities.

“ConOps will enable CDER and ORA to manage the growing complexity of the pharmaceutical landscape,” said CDER director Dr. Janet Woodcock and associate commissioner for regulatory affairs Melinda Plaisier, in a note to CDER staff.

The note goes on to highlight objectives of the agreement, including ensuring consistency, efficiency, and transparency in facility evaluations, inspections, and regulatory decision-making for marketing applications across FDA; increasing access to facility and regulatory decisional information; and meeting user fee commitments and improving the timelines for regulatory, advisory, and enforcement actions to protect public health and promote drug quality, safety, and effectiveness.

“It is essential that we mobilize to prepare for the commitments of the reauthorization of the human drug user fees,” said Woodcock and Plaisier.

The  Generic Drug User Fee Amendments II (GDUFA II), under the FDA Reauthorization Act (FDARA) signed into law on Aug. 18, 2017,  requires the agency to communicate final inspection classifications to facility owners within 90 days of an inspection starting October 2018, according to Woodcock and Plaisier. Additionally, the note states that the director and associate commissioner plan to adhere to this standard come fall 2017, and stress the importance of the program for honoring GDUFA II commitments.

Source: FDA

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.